NCT03205761 2024-10-18
COMETABreast
Spanish Breast Cancer Research Group
Phase 2 Completed
Clinical Trials
6 trialsNCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT02069093 2017-02-13
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Novartis
Phase 2 Completed
NCT00494481 2016-09-30
E3 Breast Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed